Evidence map›Paper›PMID 33123544›Full record

SynthesisFrontiers in medicine2020

Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis.

Umesha Boregowda, Abhilash Perisetti, Arpitha Nanjappa, Mahesh Gajendran, Gurusaravanan Kutti Sridharan, Hemant Goyal

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Tocilizumab and Systemic Corticosteroids in the Management of Patients with COVID-19: A Systematic Review and Meta-Analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Guideline
  9. Pooled it
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Umesha BoregowdaDepartment of Internal Medicine, Bassett Medical Center, Cooperstown, NY, United States.
Abhilash PerisettiDepartment of Gastroenterology and Hepatology, The University of Arkansas for Medical Sciences, Little Rock, AR, United States.
Arpitha NanjappaDepartment of Internal Medicine, Bassett Medical Center, Cooperstown, NY, United States.
Mahesh GajendranPaul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX, United States.
Gurusaravanan Kutti SridharanDepartment of Internal Medicine, University of Arizona, Tucson, AZ, United States.
Hemant GoyalThe Wright Center for Graduate Medical Education, Scranton, PA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

coronavirus (2019-nCoV)COVID-19SARS-C0V-2 infectiontocilizumabtocilizumab (IL-6 inhibitor)tocilizumab (TCZ)

Identifiers

PMID33123544
PMCPMC7566918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.